A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib | |
Chen, Kaiyan2,3,4; Zhang, Fanrong1,2; Pan, Guoqiang2,3,4,5; Sheng, Jiamin2,3,4,5; Ye, Junyi6; Xu, Yanjun2,3,4; Yu, Xiaoqing2,3,4; Huang, Zhiyu2,3,4; Fan, Yun2,3,4 | |
刊名 | CLINICAL LUNG CANCER |
2021 | |
卷号 | 22 |
关键词 | Crizotinib MET Non-small-cell lung cancer RET Resistance |
ISSN号 | 1525-7304 |
DOI | 10.1016/j.cllc.2020.07.007 |
通讯作者 | Fan, Yun(fanyun@zjcc.org.cn) |
资助项目 | Zhejiang Public Welfare Technology Research Program[LGF18H160017] |
WOS关键词 | CELL LUNG-CANCER ; ACQUIRED-RESISTANCE ; OPEN-LABEL ; CARCINOMAS ; PHASE-2 |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | CIG MEDIA GROUP, LP |
WOS记录号 | WOS:000608186600002 |
资助机构 | Zhejiang Public Welfare Technology Research Program |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/119772] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Fan, Yun |
作者单位 | 1.Zhejiang Canc Hosp, Dept Breast Surg, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China 4.Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China 5.Wenzhou Med Univ, Clin Med Coll 1, Dept Oncol, Wenzhou, Peoples R China 6.Bioinformat Dept, Burning Rock Biotech, Guangzhou, Peoples R China |
推荐引用方式 GB/T 7714 | Chen, Kaiyan,Zhang, Fanrong,Pan, Guoqiang,et al. A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib[J]. CLINICAL LUNG CANCER,2021,22. |
APA | Chen, Kaiyan.,Zhang, Fanrong.,Pan, Guoqiang.,Sheng, Jiamin.,Ye, Junyi.,...&Fan, Yun.(2021).A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.CLINICAL LUNG CANCER,22. |
MLA | Chen, Kaiyan,et al."A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib".CLINICAL LUNG CANCER 22(2021). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论